U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...

Nxera Pharma inks agreement with Holling Bio-Pharma to commercialize daridorexant in Taiwan: Tokyo, Japan Monday, March 3, 2025, 16:00 Hrs [IST] Nxera Pharma Co., Ltd. announces t ...

Japanese biopharma Nxera Pharma has announced two deals in a single day with partners that will commercialize its products in ...

Dr. Makoto Sugita, CMO and President of Nxera Pharma Japan, commented: “This new partnership with Holling will enable us to bring daridorexant, a potential best-in-class treatment, to the growing ...

Nxera Pharma, with major operations in Cambridge and Tokyo, has negotiated a lucrative deal in the autoimmune diseases space ...

Nxera Pharma has sold the Asia-Pacific rights to Idorsia's phase 3-stage autoimmune drug to Viatris for $10 million upfront.

Dr. Makoto Sugita, CMO and President of Nxera Pharma Japan, commented: “This new partnership with Holling will enable us to bring daridorexant, a potential best-in-class treatment, to the ...

The agreement was signed concurrently with Nxera’s assignment of its option to these same rights from Idorsia Pharmaceuticals Ltd under its agreement in July 2023 to acquire Idorsia ...